Lyell Immunopharma Analyst Ratings
Lyell Immunopharma Analyst Ratings
While ratings are subjective and will change, the latest Lyell Immunopharma (LYEL) rating was a maintained with a price target of $9.00 to $8.00. The current price Lyell Immunopharma (LYEL) is trading at is $2.40, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2023 | 233.33% | HC Wainwright & Co. | $9 → $8 | Maintains | Buy |
| 08/28/2023 | 108.33% | JP Morgan | $15 → $5 | Downgrades | Overweight → Neutral |
| 05/05/2023 | 275% | HC Wainwright & Co. | → $9 | Reiterates | → Buy |
| 03/02/2023 | 275% | HC Wainwright & Co. | $11 → $9 | Maintains | Buy |
| 01/24/2023 | 66.67% | Morgan Stanley | $7 → $4 | Maintains | Equal-Weight |
| 11/14/2022 | 191.67% | Morgan Stanley | $15 → $7 | Downgrades | Overweight → Equal-Weight |
| 11/11/2022 | — | Goldman Sachs | Downgrades | Buy → Neutral | |
| 10/17/2022 | 400% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 05/24/2022 | 400% | Goldman Sachs | $21 → $12 | Maintains | Buy |
| 03/31/2022 | 775% | Goldman Sachs | $31 → $21 | Maintains | Buy |
| 01/06/2022 | 733.33% | Morgan Stanley | $25 → $20 | Maintains | Overweight |
| 07/12/2021 | 941.67% | Morgan Stanley | → $25 | Initiates Coverage On | → Overweight |
| 07/12/2021 | 941.67% | B of A Securities | → $25 | Initiates Coverage On | → Buy |
| 07/12/2021 | 816.67% | JP Morgan | → $22 | Initiates Coverage On | → Overweight |
| 07/12/2021 | 1150% | Goldman Sachs | → $30 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/09/2023 | 233.33% | HC Wainwright & Co. | 9 美元 → 8 美元 | 維護 | 買 |
| 08/28/2023 | 108.33% | 摩根大通 | 15 美元 → 5 美元 | 降級 | 超重 → 中性 |
| 05/05/2023 | 275% | HC Wainwright & Co. | → 9 美元 | 重申 | → 購買 |
| 03/02/2023 | 275% | HC Wainwright & Co. | 11 美元 → 9 美元 | 維護 | 買 |
| 01/24/2023 | 66.67% | 摩根士丹利 | 7 美元 → 4 美元 | 維護 | 重量相等 |
| 11/14/2022 | 191.67% | 摩根士丹利 | 15 美元 → 7 美元 | 降級 | 超重 → 重量相等 |
| 11/11/2022 | — | 高盛 | 降級 | 買入 → 中性 | |
| 2022 年 10 月 17 日 | 400% | HC Wainwright & Co. | → 12 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2022 年 5 月 24 日 | 400% | 高盛 | 21 美元 → 12 美元 | 維護 | 買 |
| 03/31/2022 | 775% | 高盛 | 31 美元 → 21 美元 | 維護 | 買 |
| 01/06/2022 | 733.33% | 摩根士丹利 | 25 美元 → 20 美元 | 維護 | 超重 |
| 07/12/2021 | 941.67% | 摩根士丹利 | → 25 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 07/12/2021 | 941.67% | B of A 類證券 | → 25 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 07/12/2021 | 816.67% | 摩根大通 | → 22 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 07/12/2021 | 1150% | 高盛 | → 30 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Lyell Immunopharma (LYEL)?
Lyell Immunopharma（LYEL）的目標價格是多少？
The latest price target for Lyell Immunopharma (NASDAQ: LYEL) was reported by HC Wainwright & Co. on November 9, 2023. The analyst firm set a price target for $8.00 expecting LYEL to rise to within 12 months (a possible 233.33% upside). 7 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月9日公佈了Lyell Immunopharma（納斯達克股票代碼：LYEL）的最新目標股價。該分析公司將目標股價定爲8.00美元，預計LYEL將在12個月內升至12個月內（可能上漲233.33％）。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Lyell Immunopharma (LYEL)?
Lyell Immunopharma（LYEL）的最新分析師評級是多少？
The latest analyst rating for Lyell Immunopharma (NASDAQ: LYEL) was provided by HC Wainwright & Co., and Lyell Immunopharma maintained their buy rating.
HC Wainwright & Co. 對Lyell Immunopharma（納斯達克股票代碼：LYEL）的最新分析師評級由HC Wainwright & Co. 提供，Lyell Immunopharma維持買入評級。
When is the next analyst rating going to be posted or updated for Lyell Immunopharma (LYEL)?
Lyell Immunopharma（LYEL）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lyell Immunopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lyell Immunopharma was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Lyell Immunopharma的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Lyell Immunopharma的最新評級是在2023年11月9日公佈的，因此您應該預計下一個評級將在2024年11月9日左右公佈。
Is the Analyst Rating Lyell Immunopharma (LYEL) correct?
分析師對 Lyell Immunopharma（LYEL）的評級是否正確？
While ratings are subjective and will change, the latest Lyell Immunopharma (LYEL) rating was a maintained with a price target of $9.00 to $8.00. The current price Lyell Immunopharma (LYEL) is trading at is $2.40, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Lyell Immunopharma（LYEL）評級維持不變，目標股價爲9.00美元至8.00美元。Lyell Immunopharma（LYEL）目前的交易價格爲2.40美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。
